NovoCure Q2 Revenue Jumps 16%, Adjusted EBITDA Turns Positive, but TRIDENT Trial Misses Primary Endpoint
NVCR sits 65% above its 52-week low of $9.82.
Summary
NovoCure's Q2 2026 revenue grew 16% to $183.6M, Adjusted EBITDA turned positive at $10.8M, and the Optune Pax launch added 285 patients. However, the Phase 3 TRIDENT trial in GBM failed to meet its primary endpoint, removing a major growth driver.
Key Events · Earnings and Guidance · NVCR
-
Revenue Growth Accelerates
Q2 2026 net revenues rose 16% YoY to $183.6M, driven by 18% active patient growth to 5,128. U.S. revenue grew 9% to $103.0M, while international markets surged 25% to $74.7M.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA swung to a gain of $10.8M from a loss of $9.9M in Q2 2025, reflecting revenue growth, cost efficiencies, and a $4.9M tariff refund. Net loss narrowed to $15.7M from $40.1M.
-
TRIDENT Trial Misses Primary Endpoint
The Phase 3 TRIDENT trial evaluating earlier initiation of TTFields therapy in newly diagnosed GBM failed to show a statistically significant improvement in overall survival (median OS 17.7 vs 17.5 months, HR 0.953, p=0.519).
-
Optune Pax Launch Gains Traction
Optune Pax for pancreatic cancer contributed $1.6M in revenue and 285 active patients in its first full quarter post-FDA approval. The company also received CE Mark approval for the same indication.
Analysis · NVCR · Industrial Applications And Services
NovoCure delivered strong commercial execution with 18% active patient growth and a swing to positive Adjusted EBITDA, but the Phase 3 TRIDENT trial failure in newly diagnosed GBM removes a key near-term catalyst. The Optune Pax launch is off to a promising start with 285 active patients and $1.6M in revenue. Cash remains robust at $440.6M, though the company acknowledges it may need to raise additional capital as it expands into new indications. The mixed quarter — operational momentum offset by a clinical setback — keeps the investment thesis in flux.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVCR was trading at $16.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $9.82 to $18.92. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.